Tradestie Institutional Equity Comparison Engine · Market Close Aug 25, 2026

HUMAW vs CELUW: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CELUW Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 1–2 Matrix Metrics)

CELUW Overall Winner 6-Pillar Tally: HUMAW 0 – 0 CELUW (6 Tie) Matrix Metrics: HUMAW 2 – 1 CELUW

As of Aug 25, 2026, CELUW (CELUW) is the stronger overall head-to-head candidate over Humacyte, Inc. Warrant (HUMAW) in the Tradestie Institutional Equity Comparison Engine, winning 1–2 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). HUMAW carries a Unified Composite Score of 47.3/100 (HOLD) at $0.00 (N/M Forward P/E, N/A operating margin), whereas CELUW carries 41.3/100 (SELL) at $0.00 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While HUMAW currently prints a higher short-term Unified Composite Score (47.3/100 HOLD vs. CELUW 41.3/100 SELL), CELUW captures the overall institutional head-to-head verdict (1–2 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
  • Technical & Structure Timing Caution: HUMAW is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.0); meanwhile CELUW is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HUMAW vs CELUW
HUMAW NASDAQ
Humacyte, Inc. Warrant
Biological Products, (No Disgnostic Substances)
$0.00
-78.05% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.62β · 437% Vol
Unified Composite Score
47.3 / 100 HOLD
Tech 33.0 Fund 49.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -72.5%), weak momentum, RSI 32
RSI-14: 32.0 · SMA20: $0.01 · SMA50: $0.01
CELUW US Equity Head-to-Head Winner
CELUW
Institutional Equity
$0.00
+533.33% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.52β · 2163% Vol
Unified Composite Score
41.3 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -36.3%), weak momentum, RSI 43
RSI-14: 42.5 · SMA20: $0.00 · SMA50: $0.01

6-Pillar Scorecard Institutional Category Breakdown (HUMAW 0 – 0 CELUW)

Columns: Metric · HUMAW · CELUW
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biological Products, (No Disgnostic Substances) Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HUMAW (2) vs CELUW (1)
Institutional Metric HUMAW CELUW Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
0% ($0–$1) 2% ($0–$0) Stronger Trend CELUW
Beta / 30D Volatility
Risk Regime
0.62β · 437% Vol 1.52β · 2163% Vol Lower Realized Risk HUMAW
Unified Institutional Score
Composite Signal
47.3 / 100 (HOLD) 41.3 / 100 (SELL) Higher Composite HUMAW
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CELUW +29.91 pp
HUMAW: -84.67% · CELUW: -54.76%
3M Horizon CELUW +17.46 pp
HUMAW: -91.78% · CELUW: -74.32%
6M Horizon CELUW +3.08 pp
HUMAW: -95.45% · CELUW: -92.37%
1Y Horizon CELUW +2.38 pp
HUMAW: -98.16% · CELUW: -95.78%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HUMAW vs CELUW. Trailing 12-month operating profitability (HUMAW N/A vs CELUW N/A) and valuation multiples (HUMAW N/M vs CELUW N/M Forward P/E) are benchmarked directly in Pillar 4 below.

HUMAW ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
CELUW ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HUMAW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HUMAW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CELUW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CELUW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HUMAW Moat Profile Cyclical / Execution-Driven Positioning
Biological Products, (No Disgnostic Substances) Operator
Competes within the Biological Products, (No Disgnostic Substances) value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CELUW Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HUMAW vs CELUW Key Questions & Quantitative Answers

As of Aug 25, 2026, CELUW (CELUW) is the stronger overall head-to-head candidate over Humacyte, Inc. Warrant (HUMAW) in the Tradestie Institutional Equity Comparison Engine, winning 1–2 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). HUMAW carries a Unified Composite Score of 47.3/100 (HOLD) at $0.00 (N/M Forward P/E, N/A operating margin), whereas CELUW carries 41.3/100 (SELL) at $0.00 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While HUMAW currently prints a higher short-term Unified Composite Score (47.3/100 HOLD vs. CELUW 41.3/100 SELL), CELUW captures the overall institutional head-to-head verdict (1–2 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: HUMAW is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.0); meanwhile CELUW is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HUMAW and CELUW split Growth & Scale metrics: HUMAW posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CELUW at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, HUMAW generates N/A in USD-normalized revenue versus N/A for CELUW. In operating R&D and SG&A reinvestment, HUMAW deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CELUW.

HUMAW and CELUW trade at balanced relative valuation multiples. HUMAW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CELUW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HUMAW (N/A ROE) versus CELUW (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, HUMAW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.62β · 437% Vol realized risk). By comparison, CELUW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 2163% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Aug 25, 2026. For educational research only; not investment advice.